A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2018
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 28 Feb 2018 Planned End Date changed from 30 Jul 2018 to 2 Aug 2018.
- 28 Feb 2018 Planned primary completion date changed from 30 Jul 2018 to 2 Aug 2018.
- 28 Feb 2018 Status changed from not yet recruiting to recruiting.